Acerca de

Higher body weight is strongly linked to VTE risk because it increases inflammation and pressure in the veins. Sleep apnea itself increases the risk of clotting and heart strain. Low oxygen signals the body to make more red blood cells. Many cases of blood clots in people on TRT are linked to other medical conditions that already raise clotting risk. Doctors treat rising hematocrit early to prevent blood from reaching the point where clot risk becomes meaningful. At this level, the blood is significantly thicker, and the strain on the heart and blood vessels increases.
Similar increases in hemoglobin and hematocrit were observed in men who were anemic and in those who were not anemic, raising the possibility that androgens may be useful in the treatment of anemia of aging. A model for testosterone-induced erythrocytosis is proposed (Figure 6) that involves both EPO secretion and increased iron bioavailability (suppressed hepcidin) and that has experimental support from our work and that of others. In our studies, testosterone and estradiol levels increased during treatment, both correlated negatively and similarly with change in serum hepcidin levels, although there was direct concordance between the temporal relationship of testosterone increase and hepcidin suppression. The increased sTR levels in association with the reduced serum ferritin concentration during testosterone administration indicate that storage iron is being utilized to support the observed increase in hemoglobin concentration.
Stopping TRT because of high hemoglobin is sometimes necessary to protect your health. The goal is to avoid raising hemoglobin too quickly again. But the restart plan is usually different from the original treatment. The goal is to make sure levels return to a healthy range without dropping too low. During this time, a doctor may order repeat blood tests to watch the decline. Hemoglobin and hematocrit values often fall back into the safe range within 4 to 12 weeks, depending on the person.
A previous hemoglobin measurement from four years prior showed a hemoglobin of 13.2 g/dL. His laboratory investigations were notable for a similar picture (Table 1) with hemoglobin of 9.1 g/dL and MCV of 93 fL. His workup for an infectious, toxic, and metabolic cause of his symptoms was found to be negative. The patient was started on a 200 mg intramuscular testosterone cypionate to be taken every 14 days. Previous free testosterone was measured ten years ago and was 42 g/dL, within the normal range. Free and total testosterone were decreased at five picograms per deciliter (pg/dL) and 215.7 nanograms per deciliter (ng/dL), respectively.
Higher doses increase the chances of high hemoglobin. There are many ways to reduce risks while continuing therapy. Most people can stay safely on TRT as long as they check their labs and follow the treatment plan. When doctors follow your blood levels over time, they can catch changes early before they become a bigger health issue. Because of this, patients on TRT must get blood tests on a regular schedule.
Changes in outcomes with time were modeled using Generalized Estimating Equations with unstructured correlation matrix and controlling for baseline outcome levels. Serum hepcidin was measured by enzyme-linked immunosorbent assay (Intrinsic Life Sciences) with sensitivity of 5ng/mL, interassay coefficient of variation 12%, and range 29–254ng/mL in men (12,15). Free testosterone was calculated from total testosterone and SHBG concentrations using a published law-of-mass-action equation (14). At the time of trial’s cessation, 209 men had been randomized and 166 had completed 6 months of study intervention; these 166 men constituted the analytic sample for this investigation. Eligible participants were randomized to placebo or testosterone gel based on concealed, computer-generated randomization tables, using a block size of 6. To determine whether testosterone also stimulates EPO and erythropoiesis in older men with anemia, we performed sensitivity analyses in men who were anemic at baseline. The primary aim of The Testosterone in Older Men with Mobility Limitation Trial was to evaluate the effects of testosterone on muscle performance and physical function (13).
Another notable study is a 2020 randomized control trial of 95 hypogonadal men, showing a statistically significant increase in hemoglobin in men with unexplained anemia . There was a significant decrease in anemia prevalence and a considerable increase in erythropoietin levels after 18 weeks . Similarly, another observational study evaluated 58 patients who received 1,000 mg of testosterone undecanoate.
There was a small decrease in mean corpuscular volume and mean corpuscular hemoglobin concentration (Table 2) but no change in red cell distribution width or serum iron, iron-binding capacity, or percentage iron saturation (data not shown) in either group. Mean on-treatment hematocrit levels in men who experienced cardiovascular adverse events were similar to those without adverse events. Hemoglobin and hematocrit levels in testosterone-treated men peaked at month 3 in most participants and remained at these elevated levels for the remainder of the intervention period. Serum hepcidin and ferritin levels were within the reported reference ranges for men and similar between groups (15). For each time point (1, 3, and 6 months postrandomization), the testosterone-vs-placebo effect was estimated using treatment contrasts. Complete blood counts and red cell indices, ferritin, serum iron, iron binding capacity, and percentage saturation were measured at Quest Diagnostics (Cambridge, MA). Considering these historic yet contrasting data, one hypothesis is that testosterone stimulates EPO transiently, along with suppression of hepcidin, and these two mechanisms result in a new EPO "set point" at a higher physiologic level of hemoglobin.